Opinion
CRIMINAL ACTION 20-200
01-14-2022
UNITED STATES OF AMERICA v. TEVA PHARMACEUTICALS USA, INC. and GLENMARK PHARMACEUTICALS., USA
ORDER
R. BARCLAY SURRICK, J.
AND NOW, this 14th day of January 2022, upon consideration of Defendant Glenmark's Motion for Misjoinder and Severance (ECF No. 105), Defendant Teva's Response thereto (ECF No. 115), and Plaintiff's Response in opposition thereto (ECF No. 116), and all documents submitted in support thereof and in opposition thereto, it is ORDERED that Defendant's Motion is DENIED.
IT IS SO ORDERED.